Literature DB >> 2738160

Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

M H Holguin1, L R Fredrick, N J Bernshaw, L A Wilcox, C J Parker.   

Abstract

The observation that type III erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) are susceptible to hemolysis initiated by activated cobra venom factor complexes (CoFBb), whereas normal erythrocytes are resistant, implies that the PNH III cells are deficient in a membrane constituent that regulates this process. To isolate the inhibitory factor from normal erythrocytes, membrane proteins were first extracted with butanol and then subjected to sequential anion exchange, hydroxylapatite, and hydrophobic chromatography. Analysis by SDS-PAGE and silver stain of the inhibitory fractions showed a single band corresponding to a protein with an apparent Mr of 18 kD. PNH erythrocytes were incubated with incremental concentrations of the radiolabeled protein and then washed. In a dose-dependent fashion, the protein incorporated into the cell membrane and inhibited CoFBb-initiated lysis. This protein inhibitor functioned by restricting the assembly of the membrane attack complex at the level of C7 and C8 incorporation. By using a monospecific antibody to block the function of the inhibitor, it was shown that normal erythrocytes are rendered susceptible to CoFBb-initiated hemolysis. Analysis by Western blot of membrane proteins revealed that PNH III erythrocytes are deficient in the 18-kD protein. By virtue of its molecular weight and inhibitory activity, the 18-kD protein appears to be discrete from other previously described erythrocyte membrane proteins that regulate complement. These studies also indicate that the susceptibility of PNH III erythrocytes to reactive lysis is causally related to a deficiency of the 18-kD membrane inhibitor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738160      PMCID: PMC303946          DOI: 10.1172/JCI114172

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels.

Authors:  Y Sugita; Y Nakano; M Tomita
Journal:  J Biochem       Date:  1988-10       Impact factor: 3.387

2.  Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.

Authors:  E M Hoffmann
Journal:  Immunochemistry       Date:  1969-05

3.  Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.

Authors:  E M Hoffman
Journal:  Immunochemistry       Date:  1969-05

4.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

5.  Homologous species restriction in lysis of erythrocytes by terminal complement proteins.

Authors:  G M Hänsch; C H Hammer; P Vanguri; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

6.  Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  C J Parker; P J Baker; W F Rosse
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

7.  Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system.

Authors:  A Nicholson-Weller; J P March; C E Rosen; D B Spicer; K F Austen
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

8.  Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.

Authors:  S Schönermark; E W Rauterberg; M L Shin; S Löke; D Roelcke; G M Hänsch
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

Review 9.  Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.

Authors:  T Kinoshita; M E Medof; R Silber; V Nussenzweig
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Decay-accelerating factor is present on cultured human umbilical vein endothelial cells.

Authors:  A S Asch; T Kinoshita; E A Jaffe; V Nussenzweig
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more
  86 in total

1.  Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

2.  Homologous species restriction of the complement-mediated killing of nucleated cells.

Authors:  H Yamamoto; P Blaas; A Nicholson-Weller; G M Hänsch
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

Review 3.  Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.

Authors:  C J Parker
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

4.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Mitsuhiro Omine; Taroh Kinoshita; Hideki Nakakuma; Jaroslaw P Maciejewski; Charles J Parker; Gérard Socié
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

5.  C8 binding protein bears I antigenic determinants.

Authors:  P Blaas-Mautner; S Filsinger; B Berger; D Roelcke; G M Hänsch
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

6.  The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury.

Authors:  Masashi Sakuma; Toshifumi Morooka; Yunmei Wang; Can Shi; Kevin Croce; Huiyun Gao; Michael Strainic; M Edward Medof; Daniel I Simon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-18       Impact factor: 8.311

7.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement.

Authors:  A Nomura; K Nishikawa; Y Yuzawa; H Okada; N Okada; B P Morgan; S J Piddlesden; M Nadai; T Hasegawa; S Matsuo
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Tissue distribution of the guinea-pig decay-accelerating factor.

Authors:  K Nishikawa; S Matsuo; H Tamai; N Okada; H Okada
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

10.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.